The AHA, 340B Health, America’s Essential Hospitals, Association of American Medical Colleges, and Children’s Hospital Association yesterday filed a friend-of-the-court brief urging the U.S. Courts of Appeals for the 3rd Circuit to require drug companies to fulfill their legal obligations to provide 340B discounted drugs to eligible hospitals and health systems, regardless of whether the drugs are dispensed on site or through contract pharmacies.   
 
HHS last year sent violation letters to AstraZeneca and five other pharmaceutical companies for refusing to provide 340B discounts for drugs dispensed through contract pharmacies. The hospital groups told the court they agree with HHS’s arguments regarding the 340B statute’s meaning, the agency’s authority to enforce it, and the propriety of HHS’s violation letters. The organizations also elaborate on certain issues not already addressed in their recent friend-of-the-court brief responding to Novo Nordisk and Sanofi appeals challenging the HHS letters. 
 

Related News Articles

Perspective
With only 11 days that the House and Senate are in session together before the fiscal year concludes, much of the attention in Washington is on how Congress…
Headline
The Centers for Medicare & Medicaid Services has extended to Sept. 11 the deadline to submit comments on its proposed remedy for the unlawful payment…
Headline
AHA urged the House Energy and Commerce Committee to consider including in its draft legislation to address drug shortages legislative proposals that would…
Headline
The AHA filed its comment letter on the Department of Health and Human Services’ proposed remedy for the unlawful payment cuts to certain hospitals that…
Headline
A Modern Healthcare analysis of 340B hospitals “should be viewed with the derision it deserves,” writes AHA General Counsel and Secretary Melinda Hatton. “It…
Blog
Modern Healthcare’s putative report on CMS’ 340B remedy proposal is completely wrong and irresponsible for the following reasons. First, to reach its…